公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial | Piccart-Gebhart M.; Holmes E.; Baselga J.; De Azambuja E.; Dueck A.C.; Viale G.; Zujewski J.A.; Goldhirsch A.; Armour A.; Pritchard K.I.; McCullough A.E.; Dolci S.; McFadden E.; Holmes A.P.; Tonghua L.; Eidtmann H.; Dinh P.; Di Cosimo S.; Harbeck N.; Tjulandin S.; Im Y.-H.; CHIUN-SHENG HUANG ; Diéras V.; Hillman D.W.; Wolff A.C.; Jackisch C.; Lang I.; Untch M.; Smith I.; Boyle F.; Xu B.; Gomez H.; Suter T.; Gelber R.D.; Perez E.A. | Journal of Clinical Oncology | 307 | 277 | |
2014 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | De Azambuja E.; Holmes A.P.; Piccart-Gebhart M.; Holmes E.; Di Cosimo S.; Swaby R.F.; Untch M.; Jackisch C.; Lang I.; Smith I.; Boyle F.; Xu B.; Barrios C.H.; Perez E.A.; Azim H.A.; Kim S.-B.; Kuemmel S.; CHIUN-SHENG HUANG ; Vuylsteke P.; Hsieh R.-K.; Gorbunova V.; Eniu A.; Dreosti L.; Tavartkiladze N.; Gelber R.D.; Eidtmann H.; Baselga J. | The Lancet Oncology | 387 | 330 |